.
Finally, Gimelbrant and colleagues suggest that single-cell RNA-seq may not be suitable (or may be underpowered) for allelic gene expression analyses. We would like to refer them to data from our study 2 , in which the significance of clonal aRME is reported per gene and chromosome. When XCI is used as an internal control in the cells, it is apparent that single-cell RNA-seq has sufficient power to identify essentially all genes on the X chromosome as having clonal monoallelic gene expression. Moreover, the single-cell RNA-seq in our study identified the same imprinted genes as bulk RNAseq performed on the same primary cells 2 , thus again confirming power and accuracy. The reference 13 cited by Gimelbrant and colleagues regarding "challenges of singlecell RNA-seq, which make confident detection of less extreme bias difficult" simply reports that technical controls are needed to correctly adjust for the incomplete sensitivity of the libraries from each cell, procedures that we have advocated for and used in our studies 2, 9 . Altogether, we agree with Gimelbrant and colleagues' notion that clonal aRME occurs in mammalian cells beyond the classical cases such as antigen 14 and olfactory 15 receptors. However, it is now evident 2 to us that this phenomenon is biologically much rarer than initially thought [4] [5] [6] [7] [8] 16 , and it affects mostly genes that are weakly expressed, thus calling its functional role into question. Our study 2 provided the first genome-wide insights into primary and in vivo cells, whereas previous bulk analyses on clonal aRME used immortalized cell lines 4, 5 , which are notorious for genomic changes. (A full understanding of the clones used by Gimelbrant and colleagues in ref. 4 , gained through modern methods such as RNA and DNA sequencing, has not been possible because of the authors' unwillingness to share the cell clones.) In the future, we look forward to seeing more extensive in vivo datasets on clonal aRME, given that singlecell RNA-seq has become routine and can now be applied to resolve additional questions on monoallelic gene expression. COSMIC-3D provides structural perspectives on cancer genetics for drug discovery
To the Editor -COSMIC-3D is a comprehensive integration of cancer mutations with protein structure across the human genome and structural proteome, seeking to support the identification and characterization of protein targets for novel drug design in precision oncology.
As an interactive system to explore cancer mutations in 3D, COSMIC-3D is designed to enable greater understanding of the functional impact of mutations, generate new hypotheses on which mutations are cancer drivers and provide new opportunities for addressing these mutations pharmaceutically. This combination of genetics, structural proteomics and drug development can be best described as 'mutation-guided drug design' . There is a substantial need in precision oncology for treatments directed at specific cancer-associated mutations, to more effectively treat patient populations with specific genomic profiles. Recently, huge gains in targeted and genomic DNA sequencing are driving a growing knowledge of which mutations cause cancer. Yet, relative to these gains in genomic knowledge, there remains much scope for expansion of the repertoire of precision therapeutic drugs targeting these mutations. Concurrently, the number of publicly available protein structures has been growing exponentially. Both cancer genomic and protein structural data sources are individually great assets for scientists working in the field of oncology drug discovery. However, linking these two important resources enables a much greater understanding of the protein structural aspects of cancer, empowering targeted drug design across cancerassociated proteins.
Here we present COSMIC-3D, a bioinformatics platform that provides greater understanding of the impacts of cancer-associated mutations and how they might be challenged by small-molecule drugs, by placing these mutations in a protein structural context. We have achieved this by combining the rich cancer mutation annotations of the Catalogue of Somatic Mutations in Cancer (COSMIC) 1 with 3D human structural proteome data from the Protein Data Bank (PDB) 2 , using SIFTS 3 to translate UniProt sequence coordinates (mapped to COSMIC through sequence alignment) to positions in protein structures. COSMIC-3D currently maps cancer variant data for nearly 9,300 genes to nearly 37,000 protein structures, covering 390 key genes from the Cancer Gene Census as well as 3,700 in-frame deletions and over 64,000 nonsense mutations. The COSMIC-3D web interface (see "Data availability" and the Reporting Summary) combines a WebGL-based interactive 3D structure viewer, NGL 5 ( Fig. 1a,b) , and the Feature Viewer sequence viewer (https://doi.org/10.5281/ zenodo.345324) (Fig. 1c) . The sequence viewer shows COSMIC mutations, as well as contextual UniProt 6 protein annotations such as domains, enzyme active sites and post-translational modification sites. Users can click on mutations in the sequence viewer to display them in the structure viewer. The structure viewer displays the protein structure and small-molecule ligands, as well as protein-protein or protein-DNA interfaces where available, allowing mutations to be interpreted in the context of these functional binding sites. An additional panel provides further tools for manipulating the 3D structure view, including the ability to load precalculated, small-molecule binding site predictions and their associated 'druggability' scores, derived from fPocket 7 . Individual missense, in-frame deletion and nonsense somatic cancer mutations are mapped to protein structures and can be located and displayed in COSMIC-3D. For missense mutations, the structure viewer highlights the position of the mutation and visualizes the wild-type amino acid, as well as a model of the mutant amino acid, generated using PyMOL. This provides the opportunity to generate hypotheses on the impacts of missense mutations on protein structure and function. For example, Fig.  1a shows the COSMIC-3D visualization of the oncogenic mutation encoding NP_005219.2:p.Leu858Arg in the epidermal growth factor receptor (EGFR) protein. The mutation is mapped onto the complex of the EGFR kinase domain bound to lapatinib. The model of the mutant indicates protrusion of Arg858 into the lapatinibbinding site, which also corresponds to the top-ranked fPocket binding site prediction. This suggests that the mutant form may sterically interfere with lapatinib binding. Challenges remain in predicting these effects from the wild-type structure alone 8 , and hypotheses generated should be carefully explored. These challenges include protein dynamics-COSMIC-3D provides informative and accessible starting points for assessing local dynamic impacts across the breadth of cancer genomics. In this EGFR example, in vitro studies have shown that EGFR p.Leu858Arg increases the halfmaximal inhibitory concentration (IC 50 ) of lapatinib binding twofold 9 , indicating that the mutant form weakens lapatinib binding. This is a well-characterized example of how structural data and predictions can generate hypotheses on how mutations may alter the shape of known or predicted drugbinding sites.
COSMIC-3D shows the location of recurrent missense mutations on protein structures as 3D 'heat maps' indicating mutation frequency, immediately illustrating the structural and functional contexts of these mutations. This is intended to highlight key cancer driver mutations such as ones occurring at the Arg248 and Arg273 residues in the DNA-binding site of the TP53 protein (NP_000537.3) (Fig. 1b) , as well as less well-characterized putative targets.
In summary, COSMIC-3D provides a regularly updated system to explore cancer-associated mutations in a protein structural context. The COSMIC-3D 'human structural proteome of oncology' aims to empower the drug discovery process with cancer genomics. COSMIC-3D is built to aid the identification of cancerassociated mutations that are cancer drivers of structural and functional importance and to highlight how these mutations interact with known and predicted drug-binding sites. The unique combination of protein structure, mutation location and recurrence with druggability predictions made accessible in COSMIC-3D presents exciting possibilities for precision medicine by enabling high-resolution mutation-guided drug discovery.
reporting summary
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
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